Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson’s disease and beyond

키워드

참고문헌 (57)

1. Paisan-Ruiz C, "Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease", Neuron, 44, pp.595~600 (2004)
2. Zimprich A, "Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology", Neuron, 44, pp.601~607 (2004)
3. Bialik S, "Lethal weapons: DAP-kinase, autophagy and cell death: DAP-kinase regulates autophagy", Curr Opin Cell Biol, 22, pp.199~205 (2010)
4. Kuo JC, "The tumor suppressor DAPK inhibits cell motility by blocking the integrin-mediated polarity pathway", J Cell Biol, 172, pp.619~631 (2006)
5. Kuo JC, "Uncoordinated regulation of stress fibers and focal adhesions by DAP kinase", J Cell Sci, 116, pp.4777~4790 (2003)
6. Chuang YT, "The tumor suppressor death-associated protein kinase targets to TCR-stimulated NF-kappa B activation", J Immunol, 180, pp.3238~3249 (2008)
7. Chuang YT, "Tumor suppressor death-associated protein kinase is required for full IL-1beta production", Blood, 117, pp.960~970 (2011)
8. Bialik S, "The death-associated protein kinases: structure, function, and beyond", Annu Rev Biochem, 75, pp.189~210 (2006)
9. Wang LH, "Mixedlineage kinases: a target for the prevention of neurodegeneration", Annu Rev Pharmacol Toxicol, 44, pp.451~474 (2004)
10. Ferrer I, "Active, phosphorylation-dependent mitogen-activated protein kinase(MAPK", ERK), stress-activated protein kinase, JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies, pp.J Neural Transm, 2001[DOI]
11. Parkinson Study G, "The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD", Neurology, 62, pp.330~332 (2004)
12. Zhang D, "Receptor-interacting protein(RIP)kinase family", Cell Mol Immunol, 7, pp.243~249 (2010)
13. Meylan E, "The RIP kinases: crucial integrators of cellular stress", Trends Biochem Sci, 30, pp.151~159 (2005)
14. Dzamko N, "The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling", PLoS One, 7, pp.e39132~ (2012)
15. Gardet A, "LRRK2 is involved in the IFN-gamma response and host response to pathogens", J Immunol, 185, pp.5577~5585 (2010)
16. Lee S, "LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction", J Neurosci, 30, pp.16959~16969 (2010)
17. Parisiadou L, "LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity", Nat Neurosci, 17, pp.367~376 (2014)
18. Tong Y, "Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice", Proc Natl Acad Sci U S A, 107, pp.9879~9884 (2010)
19. Tong Y, "Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway", Mol Neurodegener, 7, pp.2~ (2012)
20. Herzig MC, "LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice", Hum Mol Genet, 20, pp.4209~4223 (2011)
21. Thevenet J, "Regulation of LRRK2 expression points to a functional role in human monocyte maturation", PLoS One, 6, pp.e21519~ (2011)
22. Hakimi M, "Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures", J Neural Transm, 118, pp.795~808 (2011)
23. Funayama M, "An LRRK2mutation as a cause for the parkinsonism in the original PARK8 family", Ann Neurol, 57, pp.918~921 (2005)
24. Liu Z, "A Drosophila model for LRRK2-linked parkinsonism", Proc Natl Acad Sci U S A, 105, pp.2693~2698 (2008)
25. Tong Y, "R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice", Proc Natl Acad Sci U S A, 106, pp.14622~14627 (2009)
26. Alegre-Abarrategui J, "LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model", Hum Mol Genet, 18, pp.4022~4034 (2009)
27. Chen CY, "LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD", Cell Death Differ, 19, pp.1623~1633 (2012)
28. Matta S, "LRRK2controls an EndoA phosphorylation cycle in synaptic endocytosis", Neuron, 75, pp.1008~1021 (2012)
29. Martin I, "Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease", Cell, 157, pp.472~485 (2014)
30. MacLeod D, "The familial Parkinsonism gene LRRK2 regulates neurite process morphology", Neuron, 52, pp.587~593 (2006)
31. Hockey LN, "Dysregulation of lysosomal morphology by pathogenic LRRK2 is corrected by TPC2 inhibition", J Cell Sci, 128, pp.232~238 (2015)
32. Dodson MW, "Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning", Hum Mol Genet, 21, pp.1350~1363 (2012)
33. Sanchez-Danes A, "Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease", EMBO Mol Med, 4, pp.380~395 (2012)
34. Guo JL, "Distinct alpha-synuclein strains differentially promote tau inclusions in neurons", Cell, 154, pp.103~117 (2013)
35. Kim S, "Alpha-synuclein, Parkinson's disease, and Alzheimer's disease", Parkinsonism Relat Disord, 10(1), pp.9~13 (2004)
36. Culvenor JG, "Non-Abeta component of Alzheimer's disease amyloid(NAC)revisited. NAC and alpha-synuclein are not associated with Abeta amyloid", Am J Pathol, 155, pp.1173~1181 (1999)
37. Koehler NK, "Altered serum IgG levels to alpha-synuclein in dementia with Lewy bodies and Alzheimer's disease", PLoS One, 8, pp.e64649~ (2013)
38. Linnertz C, "The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease", Hum Mol Genet, 23, pp.4814~4821 (2014)
39. Lin X, "Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein", Neuron, 64, pp.807~827 (2009)
40. Kawakami F, "LRRK2 phosphorylates tubulin-associated tau but not the free molecule:LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth", PLoS One, 7, pp.e30834~ (2012)
41. Li Y, "Mutant LRRK2(R1441G)BAC transgenic mice recapitulate cardinal features of Parkinson's disease", Nat Neurosci, 12, pp.826~828
42. Moskvina V, "Analysis of genome-wide association studies of Alzheimer disease and of Parkinson disease to determine if these 2 diseases share a common genetic risk", JAMA Neurol, 70, pp.1268~1276 (2013)
43. Barrett JC, "Genomewide association defines more than 30 distinct susceptibility loci for Crohn's disease", Nat Genet, 40, pp.955~962 (2008)
44. Zhang FR, "Genomewide association study of leprosy", N Engl J Med, 361, pp.2609~2618 (2009)
45. Xavier RJ, "Unravelling the pathogenesis of inflammatory bowel disease", Nature, 448, pp.427~434 (2007)
46. Fuss IJ, "Disparate CD4+ lamina propria(LP)lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5", J Immunol, 157, pp.1261~1270 (1996)
47. Niessner M, "Altered Th1", Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction(RT-PCR), 1995, pp.101, 428~435
48. Liu Z, "The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease", Nat Immunol, 12, pp.1063~1070 (2011)
49. Franchi L, "Function of Nod-like receptors in microbial recognition and host defense", Immunol Rev, 227, pp.106~128 (2009)
50. Krutzik SR, "Activation and regulation of Toll-like receptors 2 and 1 in human leprosy", Nat Med, 9, pp.525~532 (2003)
51. Devine MJ, "Parkinson's disease and cancer: two wars, one front", Nat Rev Cancer, 11, pp.812~823 (2011)
52. Agalliu I, "Higher Frequency of Certain Cancers in LRRK2 G2019S Mutation Carriers With Parkinson Disease: A Pooled Analysis", JAMA Neurol, 72, pp.58~65 (2015)
53. Inzelberg R, "The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers", Neurology, 78, pp.781~786 (2012)
54. Saunders-Pullman R, "LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease", Mov Disord, 25, pp.2536~2541 (2010)
55. Looyenga BD, "Chromosomal amplification of leucine-rich repeat kinase-2(LRRK2)is required for oncogenic MET signaling in papillary renal and thyroid carcinomas", Proc Natl Acad Sci U S A, 108, pp.1439~1444 (2011)
56. Gehrke S, "Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression", Nature, 466, pp.637~641 (2010)
57. Gingras AC, "eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation", Annu Rev Biochem, 68, pp.913~963 (1999)

관련 논문AI추천